Suffering from Prurigo Nodularis?

This ICON/Trevi 1 year study aims to determine the evaluate the safety, tolerability, and effectiveness of nalbuphine as a treatment for the itching related to Prurigo Nodularis (PN). This study will also evaluate participant’s itch-related quality of life and sleep quality. There are currently no approved treatments specifically for people who experience itching due to Prurigo Nodularis.

To participate in your local study, please contact (949) 844-0442 or fill out the form below.

Protocol # TR-11

Share this post

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Call us, write us, or knock on our door.

Lorem ipsum dolor sit amet, consectetur adiop iscing elit, sed do eiusmod tempor inci didunt ult labore et dolore magna aliqua.

Suffering from Atopic Dermatitis?

Trial – Syneos Health/Eli Lilly

Eli Lilly and Company are conducting a study on an investigational drug called XXXXXXXXX as a possible treatment for moderate-to-severe atopic dermatitis (AD). This study will also include 2 vaccines commonly used in adults with AD: meningococcal vaccines (MCV) and tetanus, diphtheria, and pertussis (Tdap).